GPC chronicles

GPC (FSE:GPC; GPCB), which was founded in 1997, originally was a genomics- and proteomics-based drug discovery company focused on oncology, infectious diseases and immunology. Since it in-licensed Orplatna satraplatin in 2002, its focus has turned to oncology drug discovery and development. At March 31, GPC had E111.3 million ($148.8 million) in cash. The weekly stock price for GPC is tracked below against selected events since the company's IPO on the Neuer Markt of the Frankfurt Stock Exchange in May 2000. A. 5/31/00 - Raises E118.6M ($110.6M) in an IPO on the Neuer MarktB. 1/17/01 - Byk Gulden, now part of Nycomed, agrees to pay up to $100M for GPC to use its functional genomics platform to identify tumor-specific targets to induce apoptosis in cancer cells

C. 11/1/01 - Altanawill make an equity investment of E34.2M ($30.5M), giving it 8.3% of GPCD. 6/6/02 - PanTherix, now non-operational, recieves exclusive worldwide rights to GPC's antibacterials program in exchange for a note that converts into $2.5M of PanTherix shares. GPC said it regained the program in 2003 after PanTherix did not fulfill diligence obligations...